Inflammation

Gerald Weissmann: Inflammation in rheumatic disease
Bruce N Cronstein, Jill P Buyon, Steven B Abramson

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216770; DOI: 10.1136/annrheumdis-2019-216770
LACC1 gene mutation in three sisters with polyarthritis without systemic features
Ankita Singh, Deepti Suri, Pandiarajan Vignesh, Gummadi Anjani, Prince Jacob, Katta M Girisha

Annals of the Rheumatic Diseases Dec 2019, annrheumdis-2019-216263; DOI: 10.1136/annrheumdis-2019-216263
Response to: ‘Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors’ by Meyer et al
Michelle Rosenzwajg, Roberta Lorenzon, David Klatzmann

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216598; DOI: 10.1136/annrheumdis-2019-216598
Response to: ‘Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease’ by Campochiaro et al
Fleur Cohen-Aubart, Neila Benameur, Zahir Amoura, Julien Haroche

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216755; DOI: 10.1136/annrheumdis-2019-216755
Response to: ‘“Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation” by Braaten et al: another point of view’ by Cappelli et al
Laura C Cappelli, Clifton O Bingham, Tawnie Braaten, Ami A Shah

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216892; DOI: 10.1136/annrheumdis-2019-216892
Interleukin-4 as an emerging therapeutic target for IgG4-related disease
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2020-216961; DOI: 10.1136/annrheumdis-2020-216961
Dupilumab as a potential steroid-sparing treatment for IgG4-related disease
Emanuel Della-Torre, Marco Lanzillotta, Mona-Rita Yacoub

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2020-216945; DOI: 10.1136/annrheumdis-2020-216945
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Tawnie J Braaten, Julie R Brahmer, Patrick M Forde, Dung Le, Evan J Lipson, Jarushka Naidoo, Megan Schollenberger, Lei Zheng, Clifton O Bingham 3rd, Ami A Shah, Laura C Cappelli

Annals of the Rheumatic Diseases Sep 2019, annrheumdis-2019-216109; DOI: 10.1136/annrheumdis-2019-216109
'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation’ by Braaten et al: another point of view
Fulvia Ceccarelli, Andrea Botticelli, Alain Jonathan Gelibter, Ilaria Leccese, Ramona Lucchetti, Enrico Cortesi, Guido Valesini, Paolo Marchetti, Fabrizio Conti

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216867; DOI: 10.1136/annrheumdis-2019-216867
Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications
Leonard Calabrese, Xavier Mariette

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216510; DOI: 10.1136/annrheumdis-2019-216510

Main menu

Inflammation

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Inflammation

Pages